What are the side effects of Trelagliptin tablets?

Trelagliptin (Trelagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved for the treatment of diabetes. Based on evidence from clinical studies, troagliptin exhibits good safety and tolerability. Common adverse drug reactions (ADRs) reported with trotagliptin in randomized controlled trials and other observational studies include allergic and skin reactions, infections, headaches, hyperuricemia, and gastrointestinal disorders. Although common, these reactions are usually mild and rarely cause patients to discontinue the drug.

In addition, some rare side effects have been reported in trolagliptin postmarketing surveillance (PMS) studies. For example, dizziness, malignancy, pancreatitis, and elevated liver enzymes have been reported with the use of trotagliptin. However, these cases are rare events and there is no clear causal link to the use of trotagliptin.

There is also evidence from systematic reviews and meta-analyses that drugs such as DPP-4 inhibitors are significantly associated with an increased risk of bullous pemphigoid, arthralgia, and longer hospitalization for heart failure in patients with preexisting cardiovascular disease. However, these findings are not a single study of trotagliptin, but rather a summary of the entire DPP-4 inhibitor drug class.

In summary, trolagliptin's side effects are generally mild, and its safety and tolerability are good compared with otherDPP-4 inhibitor drugs. However, any drug carries potential risks of side effects, so before using trotagliptin or any other drug, patients should seek medical advice and follow the doctor's instructions to use the drug correctly. Doctors will comprehensively consider factors such as condition, medical history, and drug interactions based on the patient's specific situation to ensure the safety and effectiveness of the drug.